Exciting Progress in Oncology Research with AVZO-1418/DB-1418
Recently, a significant milestone was reached in the realm of oncology research. Avenzo Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing cancer therapies, has dosed its first patient in a groundbreaking Phase 1 portion of a Phase 1/2 clinical trial. This study focuses on AVZO-1418/DB-1418, which aims to improve outcomes for patients suffering from advanced solid tumors.
Understanding AVZO-1418/DB-1418
The innovative treatment, AVZO-1418/DB-1418, is a novel bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3. Designed to selectively attack cancer cells, this therapy holds the promise of being a best-in-class option among existing treatments. By leveraging its dual-targeting mechanism, AVZO-1418/DB-1418 aims to not only enhance the effectiveness of cancer treatment but also reduce side effects typically associated with traditional therapies.
Goals of the Clinical Trial
The primary goal of this clinical study is to investigate the safety and tolerability of AVZO-1418/DB-1418 in patients with advanced solid tumors. Furthermore, the study will evaluate the preliminary clinical activity of this promising drug as a standalone treatment as well as in combination with other therapies. The open-label design allows for thorough monitoring of patient responses and safety.
Partnerships and Development
This pivotal study follows a strategic move made earlier by Duality Biotherapeutics and Avenzo, which involved entering an exclusive licensing agreement for the development and commercialization of AVZO-1418/DB-1418. Notably, Avenzo will handle all aspects of development globally, with the exception of the Greater China region. This partnership emphasizes both companies’ commitment to delivering innovative cancer therapies to the market.
About Duality Biotherapeutics
Duality Biotherapeutics stands at the forefront of biotech innovation, focusing on the discovery and development of advanced ADC therapies. The company has made significant strides, establishing several unique technology platforms, each backed by extensive intellectual property rights. With an ambitious pipeline, DualityBio conducts numerous global clinical trials across 17 countries, having successfully enrolled over 2,000 patients. This level of commitment underscores their dedication to pushing boundaries in cancer and autoimmune disease treatment.
Strategic Collaborations
In its journey to revolutionize cancer treatment, DualityBio has built strategic alliances with multinational corporations and innovative biotech firms. These collaborations enable Duality to harness vast resources and expertise, paving the way for the development of novel ADCs, including bispecific and novel-payload candidates, as well as those targeting autoimmune conditions. This synergy is crucial for optimizing research and amplifying the impact of their treatments.
Frequently Asked Questions
What is the aim of the clinical trial for AVZO-1418/DB-1418?
The goal is to assess the safety, tolerability, and preliminary clinical activity of the drug in patients with advanced solid tumors.
Which company is developing AVZO-1418/DB-1418?
Avenzo Therapeutics, Inc. is responsible for the development and commercialization of the drug.
How does AVZO-1418/DB-1418 work?
This bispecific ADC targets both EGFR and HER3 to effectively attack cancer cells while minimizing side effects.
What stage is the clinical trial currently in?
The trial has recently begun, with the first patient dosed in the Phase 1 portion of the study.
What is Duality Biotherapeutics' role in this collaboration?
Duality Biotherapeutics initially developed AVZO-1418/DB-1418 and entered into a licensing agreement with Avenzo for further development.
